Predictors of Sustained Response to Interferon-based Therapy in Chronic Hepatitis B
نویسندگان
چکیده
Objective: IFN-based therapy induces long-term remission in ~20% of CHB-patients. Identification of predictors of treatment response can facilitate the clinical decision. Methods: 168 CHB-patients treated with IFN-based therapy were studied. Predictors of end-of-treatment response (ETR) and sustained response (SR) one-year post therapy were identified by non-parametric chi-square test and correlation analysis. Results: Low baseline HBV DNA (<50,000,000 cp/ml) and high ALT level (>4xULN) were independent predictors of ETR. Low viral load was stronger predictor than high ALT level. If both factors coexist the probability of ETR was 92%. In HBeAg-negative subjects SR correlates significantly with age below 40 years, evidence of early viral response at 3rd month, fibrosis stage F<3 (METAVIR) and prolongation of treatment duration. HBeAg-seroconversion up to 6-month post-therapy was the strongest predictor of SR in HBeAgpositive patients. Conclusion: More favorable results could be achieved by pretreatment selection according to patients’ age, baseline viral load, ALT and liver fibrosis. Extension of IFN-treatment in responders may enhance the SR rate.
منابع مشابه
EFFICACY AND SAFETY OF COMBINATION THERAPY OF INTERFERON-ALPHA 2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C
Introduction: The aim of this study is to assess the therapeutic efficacy and safety of a particular brand of IFN alpha (PDferon B®) in combination with ribavirin (RlBA) on Iranian patients with chronic hepatitis C (CHC). The addition of RIBA to the standard treatment with interferon (IFN) alpha led to an improvement in sustained virologic response (SVR) from less than 20% with IFN monother...
متن کاملA MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF HEBER ON (INTERFERON ALFA-2b) IN COMBINATION WITH RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C IN IRAN
ABSTRACT Background: Combination therapy with interferon and ribavirin is the most effective treatment for chronic hepatitis C today. The aim of this study was to evaluate the efficacy and safety of thrice-weekly Heberon (interferon alfa-2b) in combination with ribavirin as first -line treatment of chronic hepatitis C. Methods: A total of97 treatment-naive patients received Heberon three milli...
متن کاملInfluence of Vitamin D Receptor Gene Polymorphisms on Response to Pegylated Interferon in Chronic Hepatitis B Egyptian Patients
Background: We explored the effect of vitamin D receptor gene (VDR) polymorphisms in response to PEG-IFN treatment in Egyptian chronic hepatitis B (CHB) patients. Methods: Two hundred hepatitis B virus (HBV) patients (42.3±10.7 years) on PEG-IFN α-2a (180 μg /kg for 48 weeks) and one hundred control subjects (37.3 ±12 years) were enrolled in the study. Vitamin D levels a...
متن کاملVitiligo Complicating chronic Hepatitis B patients treated with α-Interferon (Report of two cases)
α-Interferon is an antiviral agent used in treatment of chronic hepatitis B. Triggering of the underlying autoimmune disease or exacerbation of pre-existing auto immune disease is documented with α-interferon, but there are few reports about occurrence of autoimmune disorders such as systemic lupus erythematosus, Vitiligo, hypo and hyperthyroidism after administration of α-interferon in the lit...
متن کاملViremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C.
BACKGROUND & AIMS In chronic hepatitis C, interferon alfa induces sustained remission in less than 30% of treated patients. The aim of this study is to analyze viral status early after initiation interferon therapy as a predictor of treatment outcome. METHODS One hundred eighty-one patients with chronic hepatitis C who had been treated with interferon alfa for 12 months (median follow-up, 49 ...
متن کامل